- Home
- IMNN vs CLRB Comparison
IMNN vs CLRB Comparison
Compare IMNN & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- CLRB
- Stock Information
- Founded
- IMNN 1982
- CLRB 2002
- Country
- IMNN United States
- CLRB United States
- Employees
- IMNN N/A
- CLRB N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- CLRB Health Care
- Exchange
- IMNN Nasdaq
- CLRB Nasdaq
- Market Cap
- IMNN 13.6M
- CLRB 12.6M
- IPO Year
- IMNN 1985
- CLRB N/A
- Fundamental
- Price
- IMNN $0.88
- CLRB $0.31
- Analyst Decision
- IMNN Strong Buy
- CLRB Hold
- Analyst Count
- IMNN 2
- CLRB 1
- Target Price
- IMNN $21.50
- CLRB N/A
- AVG Volume (30 Days)
- IMNN 115.3K
- CLRB 619.5K
- Earning Date
- IMNN 05-12-2025
- CLRB 05-13-2025
- Dividend Yield
- IMNN N/A
- CLRB N/A
- EPS Growth
- IMNN N/A
- CLRB N/A
- EPS
- IMNN N/A
- CLRB N/A
- Revenue
- IMNN N/A
- CLRB N/A
- Revenue This Year
- IMNN N/A
- CLRB N/A
- Revenue Next Year
- IMNN N/A
- CLRB N/A
- P/E Ratio
- IMNN N/A
- CLRB N/A
- Revenue Growth
- IMNN N/A
- CLRB N/A
- 52 Week Low
- IMNN $0.64
- CLRB $0.22
- 52 Week High
- IMNN $3.65
- CLRB $3.51
- Technical
- Relative Strength Index (RSI)
- IMNN 45.55
- CLRB 53.36
- Support Level
- IMNN $0.82
- CLRB $0.23
- Resistance Level
- IMNN $0.98
- CLRB $0.29
- Average True Range (ATR)
- IMNN 0.06
- CLRB 0.03
- MACD
- IMNN -0.01
- CLRB 0.00
- Stochastic Oscillator
- IMNN 41.64
- CLRB 98.68
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.